Skip to main content
Erschienen in: BMC Infectious Diseases 1/2022

Open Access 01.12.2022 | Case report

Extracorporeal membrane oxygenation rescue for severe pneumocystis pneumonia with the Macklin effect: a case report

verfasst von: Guoqing Huang, Liping Zhou, Ning Yang, Ping Wu, Xiaoye Mo

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2022

Abstract

Background

Pneumocystis jirovecii pneumonia (PJP) in an immunocompromised host is often associated with the Macklin effect, which can progress to spontaneous pneumomediastinum (SPM), subcutaneous emphysema (SCE), and pneumothorax (PNX). Diagnosing the causative organism of these conditions in non-HIV infected patients and treating hypoxemia while preventing further lung damage can be challenging. This study examines the case of a non-HIV infected male with SPM, SCE, and PNX secondary to severe Pneumocystis jirovecii (PJ) infection.

Case presentation

A 53-year-old male with pure red cell aplasia (PRCA) was admitted with fever, dry cough, and shortness of breath. His respiratory function progressively deteriorated due to the development of SPM, SCE, and PNX, eventually requiring endotracheal intubation and invasive ventilation. As a result of high pressure in his airways occasioned by lung recruitment maneuvers, his pulmonary parameters worsened, necessitating veno-venous (VV) extracorporeal membrane oxygenation (ECMO) therapy. The early initiation of VV-ECMO facilitated ultra-protective lung ventilation and prevented the progression of SPM, SCE, and PNX. Traditional diagnostic assays were unrevealing, whereupon the patient resorted to the metagenomic next-generation sequencing technology for uncovering potential pathogens. Consequently, we detected a significantly higher infection by PJ in the patient’s bronchoscopy lavage fluid. Finally, the patient was successfully treated with appropriate antimicrobials and was decannulated after nine days of ECMO support.

Conclusions

SPM, SCE, and PNX are rare clinical manifestations of PJP. However, they can be considered as poor prognostic factors of the infection. Physicians should, therefore, be alert to the possibility of PJP in immunocompromised patients.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ARDS
Acute respiratory syndrome
BWA
Burrows–Wheeler alignment
CRP
C-reactive protein
EICU
Emergency intensive care unit
ESR
Erythrocyte sedimentation rate
FiO2
Fraction of inspired oxygen
LDH
Lactate dehydrogenase
mNGS
Metagenomic next-generation sequencing
NR
Normal reference
N/L
Neutrophil–lymphocyte count ratio
PCT
Procalcitonin
PEEP
Positive end-expiratory pressure
PJ
Pneumocystis jirovecii
PJP
Pneumocystis jirovecii pneumonia
PNX
Pneumothorax
PRCA
Pure red cell aplasia
P/L
Platelet–lymphocyte count ratio
SCE
Subcutaneous emphysema
SMZ-TMP
Trimethoprim/sulfamethoxazole
SPM
Spontaneous pneumomediastinum
SpO2
Pulse oxygen saturation
VV-ECMO
Veno-venous extracorporeal membrane oxygenation

Background

Pneumocystis jirovecii pneumonia (PJP) is a severe and potentially fatal opportunistic infection in immunosuppressed patients [1]. Common clinical signs of PJP include fever, chest pain, dry cough, and dyspnea [2]. Severe PJP may be associated with the Macklin effect, clinically presenting as spontaneous pneumomediastinum (SPM), subcutaneous emphysema (SCE), and pneumothorax (PNX) [3, 4]. Sherman et al. [5] and Villalona-Calero et al. [6] were the first to report that PNX and SPM complicated PJP in patients with AIDS. The Macklin effect, which is often the precursor of SPM in HIV patients, is relatively uncommon in patients without HIV—with an incidence rate of 0.4–4% [7]. In this report, we reviewed the case of a 53-year-old man with pure red cell aplasia (PRCA) who developed a life-threatening complication of PJP due to severe respiratory distress syndrome. Multiple studies have established that non-HIV infected patients with SPM, SCE, and PNX are more prone to developing severe symptoms and complications [810].

Case presentation

In October 2019, a 53-year-old man with PRCA visited the emergency department of Xiangya Hospital, Changsha, China. His family history and psycho-social history were not special. The patient had experienced acute dyspnea for 5 days, accompanied by fever and cough without sputum. To treat PRCA, the patient had taken oral prednisone irregularly before the 5-day period. On admission, he was febrile (37.9 °C), tachypneic (30 breaths/min), and had a pulse oxygen saturation (SpO2) value of 80%. His blood pressure and pulse rate were within normal ranges. The breath sounds of both lungs were clear, without dry or wet rale. Furthermore, the heart boundary was normal, and there were no heart murmurs.
The main abnormalities in laboratory findings on admission were as follows: Total leukocyte, 15.2 × 109/L (normal reference, NR: 4.0–10.0 × 109/L); neutrophils, 14.6 × 109/L (NR: 1.8–6.3 × 109/L); lymphocytes, 0.3 × 109/L (NR: 1.1–3.2 × 109/L); albumin, 17.5 g/L (NR: 40.0–55.0 × g/L); lactate dehydrogenase, 656.0 U/L (NR: 120.0–250.0 U/L); glucose, 18.92 mmol/L (NR: 3.90–6.10 mmol/L); D-dimer, 0.55 mg/L (NR: 0–0.5 mg/L); procalcitonin (PCT), 0.61 ng/mL (NR: 0–0.046 ng/mL); C-reactive protein, 116.14 mg/L (NR: 0–8.00 mg/L); and erythrocyte sedimentation rate, 120 mm/h (NR: 0–21 mm/h). The liver and kidney functions were normal. Also, the HIV test was negative. We initiated blood culture and sputum culture upon admission. Because of a low SpO2 under nasal oxygen and poor consciousness, the patient was transferred to an emergency intensive care unit (EICU). He received a series of respiratory supportive maneuvers, such as high flow oxygenation for one hour and non-invasive ventilation for two hours. Then, initial mobile chest X-ray revealed air-space opacities in the bilateral middle and lower zones and hyperlucency at the edge of mediastinum structures, which is suggestive of pneumomediastinum (Fig. 1A). In addition, a chest CT scan was performed, which showed diffuse, patchy, ground-glass opacities in bilateral lungs, along with a large pneumomediastinum, small SCE in front of the sternum, and a small left PNX (Fig. 1B, C). However, the patient’s respiratory status did not improve with the respiratory maneuvers. As a result, he was placed on endotracheal intubation, starting with invasive ventilation in emergency scenarios. The ventilatory protocol included a pressure control rate of 16 breaths/min, a fraction of inspired oxygen (FiO2) of 100%, a positive end-expiratory pressure (PEEP) of 10 cmH2O, and a driving pressure of 20 cmH2O. At that time, the patient received an anti-viral treatment, with 75 mg of oseltamivir twice daily, accompanied by 4.5 g of piperacillin-tazobactam every 8 h. This broad-spectrum antibiotic therapy because of his compromised immune system resulting from a history of prednisone medication.
The patient’s hypoxemia (PaO2 < 50 mmHg) continued into the second day of hospitalization. The medical professionals were unable to perform prone positioning and lung recruitment on the patient because these therapeutic maneuvers would worsen his hypoxemia and facilitate the progression of the Macklin effect. Emergency veno-venous (VV) extracorporeal membrane oxygenation (ECMO) was thus initiated as an ultra-protective lung ventilation strategy. The general ECMO settings were as follows: flow rate, 3.5–5 L/min; sweep, 2.0 L/min; and FiO2, 100%. Ventilator settings were adjusted after initiating VV-ECMO, with decreases in FiO2 from 100 to 40% and a PEEP from 10 cm H2O to 5 cm H2O. A chest X-ray of two-sided “white lung” after ECMO performance was shown (Fig. 1D). The patient’s blood culture and sputum culture came out negative on the third day of hospitalization, confirming no bacterial infection. The G-test value was therefore elevated (600 pg/mL, NR: < 70). The patient tested negative for common viruses, necessitating the suspension of oseltamivir administration. Since traditional diagnostic assays were unrevealing, the patient resorted to the metagenomic next-generation sequencing technology for uncovering potential pathogens. Therefore, DNA sequencing was performed based on the BGISEQ-100 platform (BGI-Tianjin, Tianjin, China). High-quality sequencing data were generated after filtering out low-quality, low-complexity, and shorter reads. Using Burrows–Wheeler Alignment (BWA, http://​bio-bwa.​sourceforge.​net/​), the data mapped to the human reference genome were excluded. The remaining data were aligned to the Microbial Genome Database from NCBI, including bacteria, viruses, fungi, and protozoa (http://​ftp.​ncbi.​nlm.​nih.​gov/​genomes/​). Finally, the mapped data were processed by removing duplicate reads for advanced data analysis. As a result, we detected a significantly higher infection by PJ in the patient’s bronchoscopy lavage fluid and confirmed the diagnosis of PJP (Fig. 2). Then, the patient was started on trimethoprim/sulfamethoxazole (SMZ-TMP) at a dose of 0.96 g every 6 h. On day 6 of hospitalization, the patient’s condition evolved with an improvement of the fever. Figures 3 and 4 showed the changes in laboratory findings following the VV-ECMO procedure. Except hemogram evaluated throughout the hospital stay, Fig. 3 also showed the alterations of neutrophil-lymphocyte count ratio (N/L) and platelet-lymphocyte count ratio (P/L), which were recognized as useful predictors of disease severity and worse prognosis. Figure 4 showed the kidney and liver functions of this patient. A temperate hepatic dysfunction on day 6 of hospitalization caused by PJ was relieved soon after protective treatment, without kidney injury. Serum lactate levels were increased at the early stage of PJP, and PCT as a marker of infection decreased gradually after the administration of SMZ-TMP.
Meanwhile, plasma D-dimer and fibrin degradation products, as two promising biomarkers to predict perioperative fibrinolysis and bleeding, increased during ECMO performance and decreased after ECMO withdrawal. As of day 9 of hospitalization, the patient had been on antimicrobial therapy for 6 days and showed progressive improvement in respiratory failure, with the disappearance of SPM and absorption of ground-glass opacities in X-ray (Fig. 1E). The ECMO cannulas were removed on day 10 of hospitalization. However, the patient needed prolonged ventilator support and tracheostomy. A repeat CT scan of the chest also showed resorption and disappearance of SPM, SCE, and PNX (Fig. 1F, G). On day 23 of hospitalization, the patient regained consciousness, with his invasive ventilation and tracheal tube removed successfully. No adverse or unanticipated events occurred. After 29 days of hospitalization, he was discharged. With two years of follow-up, the patient showed a good prognosis without recurrence. The patient could understand the duration and efficacy of the treatment.

Discussion and conclusions

We successfully used VV-ECMO in a non-HIV patient with severe PJP infection. The patient had suffered fatal respiratory failure accompanied by the Macklin effect, which progressed to SPM, SCE, and PNX. VV-ECMO was performed as a safe and effective rescue therapy to correct the aggravating hypoxemia and prevent other clinical complications. With the use of SMZ-TMP as a treatment, the patient’s condition improved, and the patient was discharged after 29 days. The discharge followed the successive removal of the patient from ECMO, invasive ventilation, and tracheal tube.
The Macklin effect often occurs in patients with pneumonia who develop acute respiratory distress syndrome (ARDS) and need invasive mechanical ventilation with high PEEP and driving pressure [3, 11]. Empirical evidence shows that SPM, SCE, and PNX rarely occur in patients without invasive mechanical ventilation [11, 12]. The exact pathophysiology involved in these complications is thought to be related to diffuse alveolar rupture. The pressure gradient between the alveoli and surrounding tissues increases once the pressure in the respiratory tract goes up, leading to the rupture of alveoli and consequent formation of interstitial emphysema. When the average pressure in the mediastinum is lower than that in the surrounding pulmonary parenchyma, the gas enters the mediastinum. The Macklin effect involves a three-step pathophysiologic process: blunt traumatic alveolar rupturing, air dissection along bronchovascular sheaths, and spreading of this blunt pulmonary interstitial emphysema into the mediastinum [3, 13]. Research suggests that pneumonia caused by several specific pathogens can trigger the Macklin effect. In 2004, a study on severe acute respiratory syndrome (SARS) patients in Hong Kong reported an 11.6% incidence rate of SPM in infected persons [14]. Udupa et al. [15] reported three cases of SCE and pneumomediastinum in children with influenza A virus subtype H1N1. Recent reports documented SPM, SCE, and PNX occurring in COVID-19 patients [1113, 1619]. Often, these patients require high PEEP, prone positioning, and frequent bronchoalveolar lavage. These procedures increase the intrathoracic pressure and barotrauma.
In the absence of such viruses, PJ rarely causes the Macklin effect. Yee et al. [20] reported a 31-year-old man with PJP suffered from respiratory failure caused by pneumomediastinum and bilateral PNX. The clinical manifestations and radiologic abnormalities of PJP are nonspecific, making it challenging to differentiate PJP from other opportunistic pulmonary infections. It is, therefore, common to miss the diagnosis of PJP in a non-HIV-infected patient. In the case presented in this study, PJ was not considered a possible infection, and so the patient did not receive early antibiotics. Such delays in administering the correct treatment result from a delay in pathogen detection [21]. Although there is no direct relationship between PJ infection and the occurrence of the Macklin effect, some researchers believe that the event of SPM, SCE, and PNX could be considered a poor prognostic factor.
SPM, SCE, and PNX hinder the upregulation of invasive ventilator pressure and the execution of therapeutic maneuvers such as prone position ventilation [22]. The wrong implementation of endotracheal intubation may potentiate damage to the tracheal wall, worsening respiratory failure [7]. For critical patients with severe respiratory failure, the Macklin effect complicates treatment. The treatment procedure VV-ECMO was initiated to solve this problem. VV-ECMO is used extensively in cardiothoracic surgery, both for hemodynamic and respiratory support [22]. It has proven to be an effective ultra-lung ventilation tool in maintaining adequate oxygenation. To ensure optimal oxygenation with VV-ECMO, the ventilator parameters can be downregulated to a safe level to prevent further alveoli injury. The use of VV-ECMO allows time for the antibiotics to show effect and for pulmonary parenchyma to heal. Antonacci et al. [23] reported using ECMO to manage a patient with SPM, SCE, and PNX during tracheal surgery. We recommend that ECMO be initiated early to rescue severe pneumonia with the Macklin effect.
In conclusion, delays in initiating antimicrobial therapy for PJP is common among non-HIV-infected patients, even among those with access to modern medical care. This delay often leads to a worse outcome. Thus, quick and sensitive diagnostic assays to confirm or rule out PJP are of urgent importance. SPM, SCE, and PNX may be a series of indicators for a poor prognosis and a more severe condition. Physicians should be alert for PJP in severe pneumonia associated with SPM, SCE, and PNX. This case report highlighted the role of VV-ECMO in successfully managing this critical situation. VV-ECMO allows ultra-protective lung ventilation, thus preventing further lung injury.

Acknowledgements

The authors would like to acknowledge the patient involved for his kind participation and all the staff of EICU for their collaboration.

Declarations

Not applicable.
Written informed consent was obtained from the patients involved for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Roux A, Gonzalez F, Roux M, Mehrad M, Menotti J, Zahar JR, et al. Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Med Mal Infect. 2014;44(5):185–98.CrossRef Roux A, Gonzalez F, Roux M, Mehrad M, Menotti J, Zahar JR, et al. Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Med Mal Infect. 2014;44(5):185–98.CrossRef
2.
Zurück zum Zitat DP KI, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE, et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. Kansenshogaku Zasshi. 2014;88(6 Suppl 11):21–5. DP KI, Valachis A, Velegraki M, Antoniou M, Christofaki M, Vrentzos GE, et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. Kansenshogaku Zasshi. 2014;88(6 Suppl 11):21–5.
3.
Zurück zum Zitat Wintermark M, Schnyder P. The Macklin effect: a frequent etiology for pneumomediastinum in severe blunt chest trauma. Chest. 2001;120(2):543–7.CrossRef Wintermark M, Schnyder P. The Macklin effect: a frequent etiology for pneumomediastinum in severe blunt chest trauma. Chest. 2001;120(2):543–7.CrossRef
4.
Zurück zum Zitat Di Saverio S, Kawamukai K, Biscardi A, Villani S, Zucchini L, Tugnoli G. Trauma-induced “Macklin effect” with pneumothorax and large pneumomediastinum, disguised by allergy. Front Med. 2013;7(3):386–8.CrossRef Di Saverio S, Kawamukai K, Biscardi A, Villani S, Zucchini L, Tugnoli G. Trauma-induced “Macklin effect” with pneumothorax and large pneumomediastinum, disguised by allergy. Front Med. 2013;7(3):386–8.CrossRef
5.
Zurück zum Zitat Sherman M, Levin D, Breidbart D. Pneumocystis carinii pneumonia with spontaneous pneumothorax. A report of three cases. Chest. 1986;90(4):609–10.CrossRef Sherman M, Levin D, Breidbart D. Pneumocystis carinii pneumonia with spontaneous pneumothorax. A report of three cases. Chest. 1986;90(4):609–10.CrossRef
6.
Zurück zum Zitat Villalona-Calero MA, Schrem SS, Phelps KR. Pneumomediastinum complicating Pneumocystis carinii pneumonia in a patient with AIDS. Am J Med Sci. 1989;297(5):328–30.CrossRef Villalona-Calero MA, Schrem SS, Phelps KR. Pneumomediastinum complicating Pneumocystis carinii pneumonia in a patient with AIDS. Am J Med Sci. 1989;297(5):328–30.CrossRef
7.
Zurück zum Zitat She WH, Chok KSH, Li IWS, Ma KW, Sin SL, Dai WC, et al. Pneumocystis jirovecii-related spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema in a liver transplant recipient: a case report. BMC Infect Dis. 2019;19(1):66.CrossRef She WH, Chok KSH, Li IWS, Ma KW, Sin SL, Dai WC, et al. Pneumocystis jirovecii-related spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema in a liver transplant recipient: a case report. BMC Infect Dis. 2019;19(1):66.CrossRef
8.
Zurück zum Zitat Weng L, Huang X, Chen L, Feng LQ, Jiang W, Hu XY, et al. Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study. BMC Infect Dis. 2016;16(1):528.CrossRef Weng L, Huang X, Chen L, Feng LQ, Jiang W, Hu XY, et al. Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study. BMC Infect Dis. 2016;16(1):528.CrossRef
9.
Zurück zum Zitat Orsini J, Gawlak H, Sabayev V, Shah K, Washburn L, McCarthy K, et al. Pneumocystis jirovecii pneumonia-associated acute respiratory distress syndrome complicated by pneumomediastinum and pneumopericardium in a non-human immunodeficiency virus-infected patient. J Clin Med Res. 2020;12(3):209–13.CrossRef Orsini J, Gawlak H, Sabayev V, Shah K, Washburn L, McCarthy K, et al. Pneumocystis jirovecii pneumonia-associated acute respiratory distress syndrome complicated by pneumomediastinum and pneumopericardium in a non-human immunodeficiency virus-infected patient. J Clin Med Res. 2020;12(3):209–13.CrossRef
10.
Zurück zum Zitat Bukamur HS, Karem E, Fares S, Al-Ourani M, Al-Astal A. Pneumocystis Jirovecii (carinii) pneumonia causing lung cystic lesions and pneumomediastinum in non-HIV infected patient. Respir Med Case Rep. 2018;25:174–6.PubMedPubMedCentral Bukamur HS, Karem E, Fares S, Al-Ourani M, Al-Astal A. Pneumocystis Jirovecii (carinii) pneumonia causing lung cystic lesions and pneumomediastinum in non-HIV infected patient. Respir Med Case Rep. 2018;25:174–6.PubMedPubMedCentral
12.
Zurück zum Zitat Manna S, Maron SZ, Cedillo MA, Voutsinas N, Toussie D, Finkelstein M, et al. Spontaneous subcutaneous emphysema and pneumomediastinum in non-intubated patients with COVID-19. Clin Imaging. 2020;67:207–13.CrossRef Manna S, Maron SZ, Cedillo MA, Voutsinas N, Toussie D, Finkelstein M, et al. Spontaneous subcutaneous emphysema and pneumomediastinum in non-intubated patients with COVID-19. Clin Imaging. 2020;67:207–13.CrossRef
13.
Zurück zum Zitat Vidrio Duarte R, Vidrio Duarte E, Gutierrez Ochoa J, Gaviria Leiva MC, Pimentel-Hayashi JA. Pneumoperitoneum in a COVID-19 patient due to the Macklin effect. Cureus. 2021;13(2):e13200.PubMedPubMedCentral Vidrio Duarte R, Vidrio Duarte E, Gutierrez Ochoa J, Gaviria Leiva MC, Pimentel-Hayashi JA. Pneumoperitoneum in a COVID-19 patient due to the Macklin effect. Cureus. 2021;13(2):e13200.PubMedPubMedCentral
14.
Zurück zum Zitat Chu CM, Leung YY, Hui JY, Hung IF, Chan VL, Leung WS, et al. Spontaneous pneumomediastinum in patients with severe acute respiratory syndrome. Eur Respir J. 2004;23(6):802–4.CrossRef Chu CM, Leung YY, Hui JY, Hung IF, Chan VL, Leung WS, et al. Spontaneous pneumomediastinum in patients with severe acute respiratory syndrome. Eur Respir J. 2004;23(6):802–4.CrossRef
15.
Zurück zum Zitat Udupa S, Hameed T, Kovesi T. Pneumomediastinum and subcutaneous emphysema associated with pandemic (H1N1) influenza in three children. CMAJ. 2011;183(2):220–2.CrossRef Udupa S, Hameed T, Kovesi T. Pneumomediastinum and subcutaneous emphysema associated with pandemic (H1N1) influenza in three children. CMAJ. 2011;183(2):220–2.CrossRef
16.
Zurück zum Zitat Di Maio S, Esposito A, Margonato A, Godino C. Massive spontaneous subcutaneous emphysema and pneumomediastinum as rare complications of COVID-19 pneumonia. J Cardiothorac Vasc Anesth. 2021;36(5):1415–8.CrossRef Di Maio S, Esposito A, Margonato A, Godino C. Massive spontaneous subcutaneous emphysema and pneumomediastinum as rare complications of COVID-19 pneumonia. J Cardiothorac Vasc Anesth. 2021;36(5):1415–8.CrossRef
17.
Zurück zum Zitat Janssen J, Kamps MJA, Joosten TMB, Barten DG. Spontaneous pneumomediastinum in a male adult with COVID-19 pneumonia. Am J Emerg Med. 2021;40:228.e3.CrossRef Janssen J, Kamps MJA, Joosten TMB, Barten DG. Spontaneous pneumomediastinum in a male adult with COVID-19 pneumonia. Am J Emerg Med. 2021;40:228.e3.CrossRef
18.
Zurück zum Zitat Marsico S, Del Carpio Bellido LA, Zuccarino F. Spontaneous pneumomediastinum and Macklin effect in COVID-19 patients. Arch Bronconeumol. 2021;57:67.CrossRef Marsico S, Del Carpio Bellido LA, Zuccarino F. Spontaneous pneumomediastinum and Macklin effect in COVID-19 patients. Arch Bronconeumol. 2021;57:67.CrossRef
19.
Zurück zum Zitat Eperjesiova B, Hart E, Shokr M, Sinha P, Ferguson GT. Spontaneous pneumomediastinum/pneumothorax in patients with COVID-19. Cureus. 2020;12(7):e8996.PubMedPubMedCentral Eperjesiova B, Hart E, Shokr M, Sinha P, Ferguson GT. Spontaneous pneumomediastinum/pneumothorax in patients with COVID-19. Cureus. 2020;12(7):e8996.PubMedPubMedCentral
20.
Zurück zum Zitat Yee D, Fu D, Hui C, Dharmadhikari N, Carino G. A rare case of 4 Ps: bilateral pneumothoraces and pneumomediastinum in pneumocystis pneumonia. R I Med J. 2020;103(5):52–4. Yee D, Fu D, Hui C, Dharmadhikari N, Carino G. A rare case of 4 Ps: bilateral pneumothoraces and pneumomediastinum in pneumocystis pneumonia. R I Med J. 2020;103(5):52–4.
21.
Zurück zum Zitat Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect. 2014;47(1):42–7.CrossRef Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect. 2014;47(1):42–7.CrossRef
22.
Zurück zum Zitat Ali HS, Hassan IF, George S. Extra corporeal membrane oxygenation to facilitate lung protective ventilation and prevent ventilator-induced lung injury in severe Pneumocystis pneumonia with pneumomediastinum: a case report and short literature review. BMC Pulm Med. 2016;16(1):52.CrossRef Ali HS, Hassan IF, George S. Extra corporeal membrane oxygenation to facilitate lung protective ventilation and prevent ventilator-induced lung injury in severe Pneumocystis pneumonia with pneumomediastinum: a case report and short literature review. BMC Pulm Med. 2016;16(1):52.CrossRef
23.
Zurück zum Zitat Antonacci F, De Tisi C, Donadoni I, Maurelli M, Iotti G, Taccone FS, et al. Veno-venous ECMO during surgical repair of tracheal perforation: a case report. Int J Surg Case Rep. 2018;42:64–6.CrossRef Antonacci F, De Tisi C, Donadoni I, Maurelli M, Iotti G, Taccone FS, et al. Veno-venous ECMO during surgical repair of tracheal perforation: a case report. Int J Surg Case Rep. 2018;42:64–6.CrossRef
Metadaten
Titel
Extracorporeal membrane oxygenation rescue for severe pneumocystis pneumonia with the Macklin effect: a case report
verfasst von
Guoqing Huang
Liping Zhou
Ning Yang
Ping Wu
Xiaoye Mo
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2022
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07550-9

Weitere Artikel der Ausgabe 1/2022

BMC Infectious Diseases 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.